- Drugs
- Wednesday, 15 Apr 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
UnitedHealth Group Inc on Wednesday reported a better-than-expected quarterly profit due to strength in the pharmacy benefit business and maintained its forecast for the year, sending the company’s shares up nearly 3% before the bell.
UnitedHealth, the first health insurer to report results this earnings season, said its quarterly numbers reflect minimal impact from COVID-19 as the U.S. incidence of the fast-spreading respiratory illness worsened only late in the quarter.
The company said Andrew Witty, head of UnitedHealth’s pharmacy benefit unit, Optum, will take a leave of absence to help lead the World Health Organization’s new initiative for COVID-19 vaccine development.
UnitedHealth said it will continue to evaluate the impact of COVID-19 as the year progresses.
“UNH’s outlook demonstrates how well protected managed care sector earnings will be from the COVID-19 crisis in near term from the unprecedented restrictions on elective health care,” Stephens analyst Scott Fidel said.
The largest U.S. health insurer said it continues to expect adjusted net earnings of $16.25 to $16.55 per share for the year, the mid-point of which is above analysts’ estimate of $16.22, according to Refinitiv IBES data.
Health insurers including UnitedHealth, Cigna Corp and Anthem Inc have announced measures to reduce patient cost sharing on COVID-19 testing and care.
For the quarter ended March 31, earnings attributable to UnitedHealth shareholders fell 2.5% to $3.38 billion, or $3.52 per share, hurt by a 7.1% jump in operating expenses.
Related Industry Updates
Middle East and Africa Botulinum Toxin Market is expected to reach US$ 453.55 million by 2030
Dec 06, 2023
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Jul 15, 2020
Pre Clinical CROs Market Real Time Analysis and Forecast 2021–2027 | Key Companies: WuXi AppTec Group , Medpace, Inc. , Pharmaceutical Product Development, LLC , Parexel International , ICON plc , MD Biosciences, Inc., etc
May 03, 2021
U.S. Government Awards Novavax $1.6 Billion for Coronavirus Vaccine
Jul 07, 2020
North America Antibiotics Market is Estimated to Grow with a CAGR of 3.9% from 2020 to 2027
Sep 24, 2020
Esteve acquires German proprietary, specialty, hospital-focused company Riemser and expands its presence in Europe
Jan 08, 2020
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
Mar 20, 2020